1. Ostrom, Q. T. et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol. 16, iv1–iv63. https://doi.org/10.1093/neuonc/nou223 (2014).
2. Louis, D. N. et al. Te 2007 WHO Classifcation of Tumours Of Te Central Nervous System. Acta Neuropathol. 114, 97–109. https://doi.org/10.1007/s00401-007-0243-4 (2007).
3. Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765–773. https://doi.org/10.1056/NEJMoa0808710 (2009).
4. Cairncross, J. G. et al. Specifc genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. JNCI J. Natl. Cancer Inst. 90, 1473–1479. https://doi.org/10.1093/jnci/90.19.1473 (1998).
5. Cavenee, W. K., Louis, D. N., Ohgaki, H., Wiestler, O. D. & International Agency for Research on Cancer. WHO Classifcation of Tumours of the Central Nervous System 4th edn. (International Agency for Research on Cancer, 2016).
6. Ceccarelli, M. et al. Molecular profling reveals biologically discrete subsets and pathways of progression in difuse glioma. Cell 164, 550–563. https://doi.org/10.1016/j.cell.2015.12.028 (2016)
7. Eckel-Passow, J. E. et al. Glioma groups based on 1p/19q, IDH, and TERTPromoter mutations in tumors. N. Engl. J. Med. 372, 2499–2508. https://doi.org/10.1056/nejmoa1407279 (2015).
8. Cancer Genome Atlas Research, N et al. Comprehensive, integrative genomic analysis of difuse lower-grade gliomas. N. Engl. J. Med. 372, 2481–2498. https://doi.org/10.1056/NEJMoa1402121 (2015).
9. Reuss, D. E. et al. Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol. 130, 407–417. https://doi.org/10.1007/s00401-015-1454-8 (2015).
10. Aibaidula, A. et al. Adult IDH wild-type lower-grade gliomas should be further stratifed. Neuro Oncol. 19, 1327–1337. https:// doi.org/10.1093/neuonc/nox078 (2017).
11. Aoki, K. et al. Prognostic relevance of genetic alterations in difuse lower-grade gliomas. Neuro Oncol. 20, 66–77. https://doi.org/10.1093/neuonc/nox132 (2018).
12. Wijnenga, M. M. J. et al. Molecular and clinical heterogeneity of adult difuse low-grade IDH wild-type gliomas: Assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratifcation. Acta Neuropathol. 134, 957–959. https://doi.org/10.1007/s00401-017-1781-z (2017).
13. Stichel, D. et al. Distribution of EGFR amplifcation, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassifcation of IDHwt astrocytoma to glioblastoma. Acta Neuropathol. 136, 793–803. https://doi.org/10.1007/s00401-018-1905-0 (2018).
14. Tabouret, E. et al. Prognostic impact of the 2016 WHO classifcation of difuse gliomas in the French POLA cohort. Acta Neuropathol. 132, 625–634. https://doi.org/10.1007/s00401-016-1611-8 (2016).
15. Brat, D. J. et al. cIMPACT-NOW update 3: Recommended diagnostic criteria for “Difuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”. Acta Neuropathol. 136, 805–810. https://doi.org/10.1007/s00401-018-1913-0(2018).
16. Arita, H. et al. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol. 126, 267–276. https://doi.org/10.1007/s00401-013-1141-6 (2013).
17. Arita, H. et al. A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol. Commun. 4, 79. https://doi.org/10.1186/s40478-016-0351-2 (2016).
18. Bleeker, F. E. et al. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum. Mutat. 30, 7–11. https://doi.org/10.1002/humu.20937 (2009).
19. Jeuken, J., Cornelissen, S., Boots-Sprenger, S., Gijsen, S. & Wesseling, P. Multiplex ligation-dependent probe amplifcation. J. Mol. Diagn. 8, 433–443. https://doi.org/10.2353/jmoldx.2006.060012 (2006).
20. Umehara, T. et al. Distribution diferences in prognostic copy number alteration profles in IDH-wild-type glioblastoma cause survival discrepancies across cohorts. Acta Neuropathol. Commun. 7, 99. https://doi.org/10.1186/s40478-019-0749-8 (2019).
21. Weller, M. et al. Molecular classifcation of difuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profling improves stratifcation of prognostically distinct patient groups. Acta Neuropathol. 129, 679–693. https://doi.org/10.1007/s00401-015-1409-0 (2015).
22. Schouten, J. P. Relative quantifcation of 40 nucleic acid sequences by multiplex ligation-dependent probe amplifcation. Nucleic Acids Res. 30, 57e–557. https://doi.org/10.1093/nar/gnf056 (2002).
23. Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987–996. https:// doi.org/10.1056/NEJMoa043330 (2005).
24. Olar, A. et al. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III difuse gliomas. Acta Neuropathol. 129, 585–596. https://doi.org/10.1007/s00401-015-1398-z (2015).
25. Petersen, J. K. et al. Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics. Neuropathol. Appl. Neurobiol. https://doi.org/10.1111/nan.12645 (2020).
26. Akyerli, C. B. et al. Use of telomerase promoter mutations to mark specifc molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type difuse gliomas. J. Neurosurg. 128, 1102–1114. https://doi.org/10.3171/2016.11.jns16973 (2018).
27. Brito, C. et al. Clinical insights gained by refning the 2016 WHO classifcation of difuse gliomas with: EGFR amplifcation, TERT mutations, PTEN deletion and MGMT methylation. BMC Cancer https://doi.org/10.1186/s12885-019-6177-0 (2019).
28. Cancer Genome Atlas Research, N. Comprehensive genomic characterization defnes human glioblastoma genes and core pathways. Nature 455, 1061–1068. https://doi.org/10.1038/nature07385 (2008).
29. Verhaak, R. G. W. et al. Integrated genomic analysis identifes clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98–110. https://doi.org/10.1016/j.ccr.2009.12.020 (2010).
30. Srividya, M. R. et al. Homozygous 10q23/PTEN deletion and its impact on outcome in glioblastoma: A prospective translational study on a uniformly treated cohort of adult patients. Neuropathology 31, 376–383. https://doi.org/10.1111/j.1440-1789.2010.01178.x (2011).
31. Carico, C. et al. Loss of PTEN is not associated with poor survival in newly diagnosed glioblastoma patients of the temozolomide era. PLoS ONE 7, e33684. https://doi.org/10.1371/journal.pone.0033684 (2012).
32. Sabha, N. et al. Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade difuse gliomas. Neuro Oncol. 16, 914–923. https://doi.org/10.1093/neuonc/not299 (2014).
33. Cristofano, A. D., Pesce, B., Cordon-Cardo, C. & Pandolf, P. P. Pten is essential for embryonic development and tumour suppression. Nat. Genet. 19, 348–355. https://doi.org/10.1038/1235 (1998).
34. Knobbe, C. B., Merlo, A. & Reifenberger, G. Pten signaling in gliomas. Neuro Oncol. 4, 196–211 (2002).
35. Sturm, D. et al. Hotspot mutations in H3F3A and IDH1 defne distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22, 425–437. https://doi.org/10.1016/j.ccr.2012.08.024 (2012).
36. Martinho, O. et al. Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas. Br. J. Cancer 101, 973–982. https://doi.org/10.1038/sj.bjc.6605225 (2009).
37. Puputti, M. et al. Amplifcation of KIT, PDGFRA, VEGFR2, and EGFR in Gliomas. Mol. Cancer Res. 4, 927–934. https://doi.org/10.1158/1541-7786.mcr-06-0085 (2006).
38. Okita, Y. et al. (11)C-methinine uptake correlates with MGMT promoter methylation in nonenhancing gliomas. Clin. Neurol. Neurosurg. 125, 212–216. https://doi.org/10.1016/j.clineuro.2014.08.004 (2014).
39. Esteller, M., Hamilton, S. R., Burger, P. C., Baylin, S. B. & Herman, J. G. Inactivation of the DNA repair gene O6-methylguanineDNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Can. Res. 59, 793–797 (1999).
40. Jeuken, J. et al. Robust detection of EGFR copy number changes and EGFR variant III: Technical aspects and relevance for glioma diagnostics. Brain Pathol. 19, 661–671. https://doi.org/10.1111/j.1750-3639.2009.00320.x (2009).